Form 4: Regeneron Director Arthur F. Ryan Sells Shares Under 10b5-1 Plan

Arthur F. Ryan, a director at Regeneron Pharmaceuticals, sold a portion of his holdings in common stock on September 3, 2024, under a pre-arranged trading plan.

Summary

• On September 3, 2024, Arthur F. Ryan, a director of Regeneron Pharmaceuticals, sold shares of the company's common stock.
• The sales were executed under a pre-arranged trading plan intended to comply with Rule 10b5-1(c), which was adopted on August 7, 2023.
• The transactions involved multiple sales at varying prices, ranging from $1,166.52 to $1,191.02 per share.
• A total of 82 shares were sold, resulting in a decrease in Ryan's direct holdings.
• Following the reported transactions, Ryan directly owns 17,682 shares of Regeneron Pharmaceuticals.
• The reporting person will provide full information regarding the number of shares sold at each separate price upon request by the Commission staff, the Company, or a security holder of the Company.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales by a company director under a pre-arranged trading plan, indicating a neutral sentiment.

Industry Context

Insider transactions are routinely monitored by investors as they can provide signals, though in this case the transactions were pre-planned under a 10b5-1 trading plan.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the director reducing their holdings, but the pre-planned nature of the sale mitigates concerns.

Key Dates